Insud Pharma acquires Viatris' women's healthcare business

Insud Pharma has completed the transaction to acquire the women’s healthcare business, primarily related to oral and injectable contraceptives, from Viatris. The transaction was first announced in October 2023.

Contraception and women’s health care represents a large and growing opportunity for emerging countries. Viatris supplies oral contraceptives to global institutions and this agreement will allow Insud Pharma to establish a position in these emerging markets and works closely with public health institutions, the company said.

This acquisition consolidates Insud Pharma's industrial presence in India with two additional manufacturing sites (Sarigam and Ahmedabad).

[Read more: Xiromed unveils generic Extina] 

Lucas Sigman, CEO of Insud Pharma, said, “This transaction is a very important acquisition in the history of the company and highlights our continuous commitment to women’s health, and more than that, since it connects directly with the responsibility we share with our Mundo Sano foundation for health in emerging countries. We are very happy to integrate two new sites in India and welcome a talented team. These two new facilities complete our network of plants in India together with Exeltis India (in Chennai) and Chemo India Formulations (in Hyderabad), having a total of more than 1,800 employees.”

Rob Spina, CEO of Xiromed said, "This is great news for the Global organization as the Viatris deal has large impact on all regions and multiple business units. For Xiromed U.S., this deal brings us an increased presence in the Women’s Health space, aligning to our strategy to become a leading Woman’s Health company worldwide."

[Read more: Xiromed launches generic Prilosec]